前房内管成形术在真实世界青光眼治疗中的多中心前瞻性研究
联合白内障手术眼(313眼)末次随访眼压与用药均显著下降,成功率61.9%,其中基线眼压>18 mmHg者成功率83%;单独手术眼(24眼)亦显著改善,未报告与管成形术相关的威胁视力并发症。
要点
- 联合白内障手术眼末次随访眼压由17.2降至14.1 mmHg,用药由2.1降至1.3(P<.001)
- 联合手术总体成功率61.9%,基线眼压>18 mmHg者达83%,43%停药
- 单独管成形术成功率35%,46%停药;无管成形术相关威胁视力并发症
核心结论
- 真实世界中iTrack管成形术单独或联合超声乳化均显著降低眼压和用药负担,安全性良好,且在多种青光眼亚型与严重程度中均有效。
研究设计与样本
- iTrack全球数据登记(iTGDR)为进行中的前瞻性真实世界多中心观察研究,器械为iTrack或iTrack Advance,可联合或不联合白内障手术。
- 联合超声乳化组313眼,单独管成形术组24眼;成功率按2024年美国眼科学会(AAO)标准定义。
主要发现
- 联合组眼压与用药由术前17.2±5.3 mmHg和2.1±1.1降至末次随访14.1±3.9 mmHg和1.3±1.4(P<.001)。
- 联合组61.9%达到成功,基线眼压>18 mmHg者升至83%;43%停药,术前为7%。
- 单独组眼压与用药由20.2±7.1 mmHg和2.3±0.9降至15.3±6.3 mmHg和1.5±1.6(P<.01),35%成功,46%停药(术前无)。
- 各青光眼亚型(原发性和继发性开角型青光眼、眼压升高)及严重程度分层眼压与用药下降均显著(P<.01)。
- 追加青光眼手术率4.9%(含激光),未报告管成形术相关威胁视力并发症;7.3%眼最佳矫正远视力下降≥2行,多与既存晚期病变或无关眼病相关。
关键数值与推荐
- 手术成功按2024年AAO标准定义。
- 联合组313眼成功率61.9%,基线眼压>18 mmHg者83%,停药比例43%(术前7%)。
- 单独组24眼成功率35%,停药46%(术前无)。
- 追加青光眼手术率4.9%,视力下降≥2行占7.3%。
临床怎么用
- 对于开角型青光眼及眼压升高患者,可考虑iTrack前房内管成形术单独或联合白内障手术以降低眼压并减少用药。
- 术前基线眼压较高(>18 mmHg)者联合手术后成功率可能更高,可作为病例选择参考。
局限性
- 为真实世界观察性登记研究,非随机对照,缺乏对照组比较。
- 单独管成形术组样本量小(24眼),结果解释需谨慎。
- 随访平均约20.5个月,长期耐久性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess real-world canaloplasty outcomes in glaucoma management using standardized data from an international registry. DESIGN: The iTrack Global Data Registry (iTGDR) is an ongoing prospective real-world multicenter observational study on ab-interno canaloplasty with the iTrack or iTrack Advance (Nova Eye Medical), with or without concomitant cataract surgery. PARTICIPANTS: Patients diagnosed with ocular hypertension or glaucoma (excluding angle-closure glaucoma). METHODS: Analysis included eyes with a minimum 12 months follow-up from the iTGDR. Both standalone canaloplasty and canaloplasty combined with cataract surgery were included. Intraocular pressure (IOP) and glaucoma medications were assessed at baseline and postoperative follow-ups. Surgical success was defined according to the 2024 American Academy of Ophthalmology (AAO) criteria. MAIN OUTCOME MEASURE: IOP, number of glaucoma medications, and success rate at last follow-up (LFU). RESULTS: Two hundred and fifty-four patients (344 eyes) were followed over a mean of 20.5 ± 7.9 months (LFU). Following combined canaloplasty and phacoemulsification (n = 313 eyes), mean IOP and medication usage reduced from 17.2 ± 5.3 mm Hg and 2.1 ± 1.1 preoperatively to 14.1 ± 3.9 mm Hg and 1.3 ± 1.4 at LFU (P < .001); 61.9% of all combined eyes achieved success (increasing to 83% in eyes with baseline IOP > 18 mm Hg), while 43% of eyes became medication-free (vs 7% preoperatively). Standalone canaloplasty (n = 24 eyes) reduced IOP and medication usage from 20.2 ± 7.1 mm Hg and 2.3 ± 0.9 to 15.3 ± 6.3 mm Hg and 1.5 ± 1.6 (P < .01); 35% of eyes achieved success, and 46% of eyes became medication-free (vs none preoperatively). IOP and medication reductions were significant across glaucoma subtypes (primary and secondary open-angle glaucoma, ocular hypertension) and severities (P < .01 for all). The rate of additional glaucoma procedures was 4.9%, including laser procedures; no canaloplasty-related sight-threatening complications were reported. A loss of ≥2 lines of corrected distance visual acuity occurred in 7.3% of eyes, most commonly in association with pre-existing advanced disease or unrelated ocular comorbidities. CONCLUSION: In real-world clinical practice, iTrack canaloplasty significantly reduced IOP and medication burden with a favorable safety profile when performed alone or with phacoemulsification and in diverse glaucoma populations.
引用
- Kerr N, Lubeck D, Barton K, et al. A Prospective, Real-World, Multicenter Study to Support the Role of Ab-Interno Canaloplasty in Glaucoma Management. Am J Ophthalmol. 2026. PMID: 41544735. doi:10.1016/j.ajo.2026.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。